# The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

> **NCT02528617** · PHASE4 · WITHDRAWN · sponsor: **Baylor Research Institute**

## Conditions studied

- Gaucher Disease Type 1
- Gaucher Disease Type 3

## Interventions

- **DRUG:** Velaglucerase alfa

## Key facts

- **NCT ID:** NCT02528617
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-07
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects accrued and no potential subjects were identified..
- **Last updated:** 2018-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02528617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02528617, "The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02528617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*